Get startedLog in
    Picture of Alembic Pharmaceuticals logo

    APLLTD — Alembic Pharmaceuticals Cashflow Statement

    0.000.00%
    in flag iconLast trade - 00:00
    HealthcareBalancedMid CapNeutral
    Balance sheetIncome statementCashflow
    Subscribe to view all data

    Annual cashflow statement for Alembic Pharmaceuticals, fiscal year end - March 31st, INR millions except per share, conversion factor applied.

    2021
    March 31st
    2022
    March 31st
    2023
    March 31st
    2024
    March 31st
    2025
    March 31st
    Period Length:12 M12 M12 M12 M12 M
    Source:ARSARSARSARSARS
    Standards:
    IAS
    IAS
    IAS
    IAS
    IAS
    Status:FinalFinalFinalFinalFinal
    Net Income/Starting Line13,6816,2013,5466,3187,072
    Depreciation
    Non-Cash Items-8231,3632,122142950
    Unusual Items
    Equity in Net Earnings/Losses
    Other Non-Cash Items
    Changes in Working Capital-58.7-4,908-1,183-1,155-9,927
    Change in Accounts Receivable
    Change in Inventories
    Change in Other Assets
    Change in Accounts Payable
    Change in Other Liabilities
    Other Operating Cash Flow
    Cash from Operating Activities14,6345,5247,2408,032880
    Capital Expenditures-6,595-4,256-4,434-3,275-5,636
    Purchase of Fixed Assets
    Other Investing Cash Flow Items-1,793537-41.868.6-47.9
    Sale of Fixed Assets
    Sale/Maturity of Investment
    Change in Net Investments
    Purchase of Investments
    Other Investing Cash Flow
    Cash from Investing Activities-8,388-3,720-4,476-3,206-5,684
    Financing Cash Flow Items-9,335-520-482-494-786
    Other Financing Cash Flow
    Total Cash Dividends Paid
    Net Issuance / Retirement of Stock
    Net Issuance / Retirement of Debt
    Cash from Financing Activities-5,974-2,174-2,620-4,3794,437
    Foreign Exchange Effects
    Beginning Cash Balance
    Ending Cash Balance
    Net Change in Cash262-370144447-367